On the one hand, NSAIDs could play a role as modifier factors of inflammation secondary to LRRK2 variants; on the other hand, NSAIDs intake could represent a marker of another determinant of reduced PD risk (for instance, caffeine intake or smoking) which is associated to NSAIDs use [48]. The gene discussed is LRRK2; the disease is Parkinson disease.